Benjamin P. Saylor
Saylor is content managing editor for Urology Times.
How Sanofi’s discontinuation of BCG affects patients, clinicians
Sanofi Pasteur recently announced that it is discontinuing its BCG products TheraCys and ImmuCyst, prompting fears of a shortage of BCG for bladder cancer patients. In this interview, Dr. Benjamin J. Davies, associate professor of urology at the University of Pittsburgh School of Medicine, discusses the implications of the announcement and what’s next for patients and clinicians.
Top apps for urologists
From AUA guidelines to a prostate cancer risk calculator, here are some useful apps recommended by urologists.
Outcomes Analysis: Decline observed in PSA-based screening for PCa
Studies about ProPublica's Surgeon Scorecard, urology participation in accountable care organizations, and Twitter were among the take-home messages in outcomes analysis at the 2016 AUA annual meeting. The take-homes were presented by Christopher Saigal, MD, MPH, of the University of California, Los Angeles.
Kidney Ca: Cytoreductive nephrectomy appears to be protective
Other kidney cancer research included an 8-gene panel that was able to predict high tumor grade in biopsy specimens and a review of perioperative transfusion’s effect on recurrence-free and overall survival.
Peri-op transfusion raises short-term morbidity risk
A retrospective analysis looks at the short-term morbidity associated with transfusion among patients in the National Surgical Quality Improvement database.
AUA 2016: Experts offer guidance on the meeting
To guide you through the 2016 AUA annual meeting and help maximize your time, Urology Times’ editorial board has reviewed the program to identify the key trends and noteworthy research at this year’s meeting.
Uro Pipeline: Trial launched for drugs' use in metastatic, hormone-sensitive PCa
A novel oral TRT agent, bladder control system, and localized prostate cancer agent are among other treatments in the pipeline discussed in this round-up.
Uro Pipeline: FDA grants priority review to advanced bladder Ca agent
Also look for coverage of products in the pipeline for bladder pain syndrome/interstitial cystitis, prostate cancer, and male infertility.
Study: Minority of urologists treat Peyronie’s disease
Peyronie’s disease (PD) is surgically treated by a minority of urologists, and urologists who subspecialize in andrology perform a disproportionate number of procedures to treat the condition. Those were among the findings of a case-log analysis that was presented at the 2015 AUA annual meeting in New Orleans and subsequently published in Urology (2016; 87:205-9).

Poll

View Results